Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

To join this study, you need to be an adult with Rheumatoid Arthritis (RA) that was diagnosed at least three months ago. Your RA should be moderate to severe, meaning you still have joint pain and swelling. You also need to have tried another RA medicine called a TNF inhibitor in the past, but it either didn't work well enough, or you couldn't tolerate it. You should also be taking a stable dose of methotrexate for at least three months, along with folic acid supplements.

There are also some reasons why you might not be able to join. For example, if you have another type of inflammatory joint condition besides RA, or if you've already taken certain other RA medicines called JAK inhibitors, you won't be eligible. The study team will check all these details carefully with you.

If you join this study, it's important to know what to expect. You'll be taking either a daily upadacitinib pill (and a 'dummy' injection every other week) or having an adalimumab injection every other week (and a 'dummy' pill every day). These 'dummy' treatments look just like the real medicine but contain no active drug. This helps keep the study fair, as neither you nor the doctors will know which actual treatment you're getting.

You'll need to attend regular visits at a hospital or clinic. During these visits, the study team will carry out medical checks to see how you're doing and if the medicine is helping. They'll also monitor you closely for any side effects. You'll likely fill out questionnaires about how you're feeling. The study involves two main periods, and after the first period, if you're doing well, you'll continue with the same assigned treatment. You'll then have follow-up visits for about 30 to 70 days after your last dose.